Docetaxel

Χώρα: Νέα Ζηλανδία

Γλώσσα: Αγγλικά

Πηγή: Medsafe (Medicines Safety Authority)

Δραστική ουσία:

Docetaxel trihydrate 100.71mg equivalent to anhydrous docetaxel 80 mg

Διαθέσιμο από:

REX Medical Ltd

INN (Διεθνής Όνομα):

Docetaxel trihydrate 100.71 mg (equivalent to anhydrous docetaxel 80 mg)

Δοσολογία:

80 mg/mL

Φαρμακοτεχνική μορφή:

Concentrate for infusion

Σύνθεση:

Active: Docetaxel trihydrate 100.71mg equivalent to anhydrous docetaxel 80 mg Excipient: Citric acid Polysorbate 80 Ethanol Water for injection

Μονάδες σε πακέτο:

Vial, glass, Diluent, 6 mL

Kατηγορία:

Prescription

Τρόπος διάθεσης:

Prescription

Κατασκευάζεται από:

Cipla Ltd

Θεραπευτικές ενδείξεις:

Docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed. Docetaxel in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy. Docetaxel in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours express HER2 and who previously have not received chemotherapy for metastatic disease.

Περίληψη προϊόντος:

Package - Contents - Shelf Life: Vial, glass, Diluent - 6 mL - 24 months from date of manufacture - Vial, glass, concentrate solution - 80 mg - 24 months from date of manufacture stored at 2° to 8°C (Refrigerate, do not freeze)

Ημερομηνία της άδειας:

2006-06-23